DOCS · Investment summary · as of 4 August 2026
Priced below what the business already delivers
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $21.66, DOCS requires a -14% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 13%.
The ranking statistic lives on the growth axis and the axes AGREE (+28.40pp margin-axis slack against +26.61pp growth-axis at the NTM base), so the declaration is reported rather than load-bearing.
The value rests on an exit multiple of 37.8x, a terminal operating margin of 34% and a 10.7% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: NAMED CAUSE, not a valuation bear case.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The ranking statistic lives on the growth axis and the axes AGREE (+28.40pp margin-axis slack against +26.61pp growth-axis at the NTM base), so the declaration is reported rather than load-bearing. |
| What do we forecast? | Revenue growth of 13% demonstrated; a terminal operating margin of 34%; an exit multiple of 37.8x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +26.6 percentage points. |
| What is it worth? | Twelve-month target $24.98, +15% from the struck price. Scenario-weighted expected return net of costs +15.3%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| FY2027 (~May 2027) | The demonstrated +13.1% growth path, via management's own stated link… | Net revenue retention prints at or above 105% | Net revenue retention prints below 105% |
| FY2027 | GAAP revenue | FY2027 revenue lands at or above the $664m guidance floor | FY2027 revenue lands below the $664m guidance floor |
| FY2027-FY2028 | The impairment case's assumed 0.25 probability — realised… | The >=$500k customer cohort's share of revenue falls at or above 78% for two consecutive fiscal years, or the largest… | The >=$500k customer cohort's share of revenue falls below 78% for two consecutive fiscal years, or the largest… |
| any quarter from FQ2-2027 | The 34.0% terminal margin AND the 25.9% guided GAAP-equivalent… | TTM GAAP operating margin falls at or above 22.0% in any two consecutive quarters | TTM GAAP operating margin falls below 22.0% in any two consecutive quarters |
NAMED CAUSE, not a valuation bear case. Concentrated pharmaceutical marketing budgets, contracting, mediated by agencies that can aggregate several disclosed customers into one decision. In FY2026 a SINGLE CUSTOMER crossed 10% of revenue for the first time in Doximity's history (Customer B, 11%); the >=$500k cohort is 125 customers producing 83% of revenue. The company discloses that customers buy indirectly through marketing agencies 'some of whom represent a number of customers', so THE DISCLOSED CONCENTRATION IS A FLOOR, not A LEVEL.
Estimated probability 25%, against the 22% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit on valuation and opportunity cost when the forward 12-month expected return falls below 0% net of costs. E[R] > 0 is the standard; there is NO percentage hurdle — the 4.7% cash hurdle was retired 28 July 2026 and must not be reintroduced. On approach to the $24.98 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | NAMED CAUSE, not a valuation bear case. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +26.6 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: NAMED CAUSE, not a valuation bear case. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $18.91, which forces an immediate review.